OVERVIEW OF ACTIVITY
Copy
This unique educational activity will combine the powers of art and science to communicate the complex pathways, processes and structures that define the current and emerging breast cancer treatment landscape. The Atlas of Molecular Oncology: Critical Pathways in Breast Cancer Treatment will provide clinicians with a concise, easy to understand slide resource to facilitate their knowledge and application of novel therapeutic approaches.
TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.
LEARNING OBJECTIVES
- Differentiate among the unique HER2-directed investigational agents currently in Phase III clinical development.
- Recognize practical and investigational strategies to maximize the clinical utility of endocrine therapy in the management of ER-positive breast cancer.
- Educate patients about the benefits and risks of bevacizumab in combination with evidence-based chemotherapeutic partners.
- Critique the available data with multikinase inhibitors in the management of metastatic breast cancer.
- Assess the scientific rationale for continuation of biologic therapy at the time of first disease progression.
- Define the role of the immune system in mediating the activity of cancer vaccine therapy.
- Explain the scientific rationale for selectively treating triple-negative and/or BRCA-deficient breast tumors with PARP inhibitors.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity contains slides. To receive credit, the participant should review the CME information, review the slide presentations and complete the Post-test and Educational Assessment and Credit Form located on our website at CME.ResearchToPractice.com.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Goss had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Chang — Consulting Agreement: Boehringer Ingelheim Pharmaceuticals Inc; Speakers Bureau: GlaxoSmithKline. Dr Miller — Consulting Agreement: Bristol-Myers Squibb Company; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. Dr Shulman — Advisory Committee and Study PI: EMD Serono Inc. Dr Slamon — Honoraria: Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Paid Travel: Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis; Stock Ownership: Amgen Inc, Pfizer Inc, Schering-Plough Corporation. Dr Tutt — Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Honoraria: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from EMD Serono Inc and Genentech BioOncology.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Review date: June 2010
Expiration date: June 2011
